Recruiting studies: Progressive Metastatic Castrate Resistant Prostate Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Canc
Phase 1 · 2 location(s) · Weill Medical College of Cornell University · NCT04886986 Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic
Phase 1/Phase 2 · 4 location(s) · Weill Medical College of Cornell University · NCT04946370 Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer
Phase 1 · 1 location(s) · Beijing Biotech · NCT07641049 A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-
Phase 3 · 1 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT07311694 A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC
Phase 1/Phase 2 · 2 location(s) · C Ray Therapeutics · NCT07567521 An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegal
Phase 1/Phase 2 · 33 location(s) · Novartis Pharmaceuticals · NCT07206056 Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617
Phase 2 · 1 location(s) · Ebrahim S Delpassand · NCT06972628

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.